



June 29, 2023

**BSE Limited**

Department of Corporate Services,  
P. J. Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**Mumbai - 400 051.**

*Dear Sir/Madam,*

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 ('Listing Regulations').**

We are pleased to enclose a Press release regarding achievement of key milestone for the Company's Phase 1 Clinical Stage MALT1 inhibitor program that is partnered with AbbVie Inc., towards treatment across a range of hematological cancers.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS - 11973)**

**Encl: a/a**



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

## Lupin Announces Achievement of Key Milestone for its Phase 1 Clinical Stage MALT1 inhibitor Program

- Lupin's proprietary MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor is a protein involved in T-cell and B-cell lymphocyte activation
- Lupin has received additional USD 25 million as part of successful achievement of key milestones

**Mumbai, India, June 29, 2023:** Global pharma major Lupin Limited (Lupin) today announced the achievement of a key milestone for its novel MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program that is partnered with AbbVie Inc. (AbbVie) towards treatment across a range of hematological cancers.

As part of the agreement, Lupin has received USD 25 million from AbbVie for initiation of Phase 1 clinical studies successfully. Lupin had earlier received USD 30 million from AbbVie for achievement of other milestones in the program.

Lupin and AbbVie inked the licensing, development, and commercialization agreement in 2018 for this novel oncology drug to treat Hematological Cancers. Lupin's MALT1 inhibitor developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination.

"This achievement is further validation of our ability to successfully develop novel treatments for unmet needs. We look forward to continued successful development of this important treatment for patients with difficult-to-treat cancers," said **Nilesh Gupta, Managing Director, Lupin.**

Lupin's Novel Drug Discovery and Development (NDDD) team is focused on building a pipeline of highly differentiated and innovative new chemical entities in the oncology space.

### About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

Follow us on:

Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

**For further information or queries please contact –**

**Shweta Munjal**

Vice President & Global Head – Corporate Communications

Email: [shwetamunjal@lupin.com](mailto:shwetamunjal@lupin.com)